1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Medtronic’s Extravascular ICD Hits Targets In Trial; Will Soon Compete With Boston Scientific’s S-ICD

 
• By Reed Miller

Results from the pivotal trial of Medtronic’s EV ICD extravascular ICD, presented at the European Society of Cardiology congress in Barcelona, imply that Medtronic will be able to launch the device in Europe by the end of this year and in the US in 2023.

EV ICD extravascular lead for medtronic aurora ev icd
Extravascular lead for Medtronic's EV ICD • Source: Medtronic

Medtronic is on track to bring its unique extravascular implantable cardioverter defibrillator (EV ICD) to market in the next year after results from the pivotal trial of the device showed it can safely and reliably terminate ventricular arrhythmias.

Like traditional ICDs, Medtronic’s EV ICD can terminate ventricular arrhythmias with shocks of up to 40 joules, but it has a single substernal lead instead of a transvenous lead

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By Marion Webb

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.